Literature DB >> 22396129

Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2-3.

Long Fu Xi1, Mark Schiffman, Laura A Koutsky, Ayaka Hulbert, Shu-Kuang Lee, Victor Defilippis, Zhenping Shen, Nancy B Kiviat.   

Abstract

Although the lineages of human papillomavirus type 31 (HPV31) variants are recognized, their clinical relevance is unknown. The purpose of our study was to examine risk of cervical intraepithelial neoplasia Grades 2-3 (CIN2/3) by HPV31 variants. Study subjects were women who participated in the atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion Triage Study and who had HPV31 infections detected at one or more visits. They were followed semi-annually over 2 years for detection of HPV DNA and cervical lesion. HPV31 isolates were characterized by DNA sequencing and assigned into 1 of 3 variant lineages. CIN2/3 was histologically confirmed in 127 (27.0%) of the 470 HPV31-positive women, 83 diagnosed at the first HPV31-positive visit and 44 thereafter. The odds ratio for the association of 2-year cumulative risk of CIN2/3 was 1.7 (95% CI: 1.0-2.9) for infections with A variants and 2.2 (95% CI: 1.2-3.9) for infections with B variants as compared to those with C variants. Among women without CIN2/3 at the first HPV31-positive visit, the risk of subsequent CIN2/3 was 2.2-fold greater for those with A variants (95% CI: 1.0-4.8) and 2.0-fold greater for those with B variants (95% CI: 0.9-4.9) as compared to those with C variants. Similar associations were observed when CIN3 was used as the endpoint. The findings from our study help to tag HPV31 variants that differ in risk of CIN2/3 and to explain in part why some HPV31 infections regress spontaneously and others lead to disease progression.
Copyright © 2012 UICC.

Entities:  

Mesh:

Year:  2012        PMID: 22396129     DOI: 10.1002/ijc.27520

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; Zhonghu He; Rachel L Winer; Ayaka Hulbert; Shu-Kuang Lee; Yang Ke; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2012-07-11       Impact factor: 7.396

Review 2.  Human papillomavirus genome variants.

Authors:  Robert D Burk; Ariana Harari; Zigui Chen
Journal:  Virology       Date:  2013-08-31       Impact factor: 3.616

3.  Short-term natural history of high-risk human papillomavirus infection in mid-adult women sampled monthly.

Authors:  Tsung-chieh Jane Fu; Long Fu Xi; Ayaka Hulbert; James P Hughes; Qinghua Feng; Stephen M Schwartz; Stephen E Hawes; Laura A Koutsky; Rachel L Winer
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

4.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Association of Human Papillomavirus 31 DNA Load with Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.

Authors:  Xia Liu; Mark Schiffman; Ayaka Hulbert; Zhonghu He; Zhenping Shen; Laura A Koutsky; Long Fu Xi
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

6.  Human papillomavirus genomics: past, present and future.

Authors:  Ariana Harari; Zigui Chen; Robert D Burk
Journal:  Curr Probl Dermatol       Date:  2014-03-13

7.  Lineages of oncogenic human papillomavirus types other than type 16 and 18 and risk for cervical intraepithelial neoplasia.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; James P Hughes; Rachel L Winer; Constance Mao; Ayaka Hulbert; Shu-Kuang Lee; Zhenping Shen; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2014-09-13       Impact factor: 13.506

8.  Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.

Authors:  Ariana Harari; Zigui Chen; Ana Cecilia Rodríguez; Allan Hildesheim; Carolina Porras; Rolando Herrero; Sholom Wacholder; Orestis A Panagiotou; Brian Befano; Robert D Burk; Mark Schiffman
Journal:  J Infect Dis       Date:  2015-10-30       Impact factor: 5.226

9.  Prevalence of human papillomavirus variants and genetic diversity in the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North-East Brazil.

Authors:  Ana Pavla Almeida Diniz Gurgel; Bárbara Simas Chagas; Carolina Medeiros do Amaral; Kamylla Conceição Gomes Nascimento; Lígia Rosa Sales Leal; Jacinto da Costa Silva Neto; Maria Tereza Cartaxo Muniz; Antonio Carlos de Freitas
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

10.  Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61).

Authors:  Zigui Chen; Mark Schiffman; Rolando Herrero; Rob DeSalle; Kathryn Anastos; Michel Segondy; Vikrant V Sahasrabuddhe; Patti E Gravitt; Ann W Hsing; Paul K S Chan; Robert D Burk
Journal:  Virology       Date:  2018-01-11       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.